Katherine Eban

Katherine Eban is an American investigative journalist and author known for her extensive reporting on pharmaceutical industry fraud, public health issues, and corporate corruption. Her work has appeared in publications including Vanity Fair, The New York Times, Fortune, and Self magazine. Her 2019 book "Bottle of Lies: The Inside Story of the Generic Drug Boom" exposed widespread problems in the global generic drug industry, particularly manufacturing issues in overseas facilities. The book was named one of the New York Times' 100 Notable Books of 2019 and received the Cornelius Ryan Award for non-fiction. Her earlier book "Dangerous Doses: A True Story of Cops, Counterfeiters and the Contamination of America's Drug Supply" (2005) investigated criminal counterfeit drug networks in the United States. The book led to Congressional hearings and helped shape policy reforms in the pharmaceutical supply chain. Eban is a Andrew Carnegie fellow and has served as a Rhodes Scholar at Oxford University. Her investigative work has received awards from organizations including the New York Press Club and the Overseas Press Club.

Readers praise Eban's thorough research and ability to make complex pharmaceutical industry topics accessible. On "Bottle of Lies," readers frequently note the eye-opening revelations about generic drug manufacturing and quality control issues. Multiple Amazon reviewers called the book "terrifying" in its implications for patient safety. Readers appreciate: - Clear explanation of technical concepts - Detailed documentation and sourcing - Narrative style that maintains interest - Real-world impact of her investigations Common criticisms: - Some find the level of detail overwhelming - A few readers note repetitive sections - Technical terminology can be challenging for general audiences Ratings across platforms: Amazon: "Bottle of Lies" - 4.7/5 from 1,900+ reviews Goodreads: "Bottle of Lies" - 4.4/5 from 7,000+ ratings "Dangerous Doses" - 4.2/5 from 300+ ratings One frequent reader comment is that the books changed how they view generic medications. Healthcare professionals often cite her work in discussions of pharmaceutical safety.

Dangerous Doses: A True Story of Cops, Counterfeiters, and the Contamination of America's Drug Supply (2005) Investigates pharmaceutical counterfeiting networks in the United States and the law enforcement efforts to combat them.

Bottle of Lies: The Inside Story of the Generic Drug Boom (2019) Examines the generic drug industry's practices, manufacturing standards, and FDA oversight, with particular focus on Ranbaxy Laboratories.

The Botany of Empire in the Long Eighteenth Century (2016) Historical analysis of how botanical exploration and documentation intersected with imperial expansion and scientific advancement.

Dangerous Medicine: The Story behind Human Experiments with Hepatitis (2023) Documents the history of human hepatitis experiments conducted on mentally disabled children at Willowbrook State School and their ethical implications.

Sam Quinones focuses on investigative reporting about pharmaceutical companies and drug trafficking. His books "Dreamland" and "The Least of Us" examine the opioid crisis and methamphetamine epidemic through detailed research and first-hand accounts.

Barry Meier specializes in coverage of healthcare corporations and medical products. His work "Pain Killer" investigated Purdue Pharma's role in the opioid crisis through interviews with former employees and analysis of internal documents.

Gerald Posner writes about pharmaceutical industry history and corporate misconduct. His book "Pharma" traces the development of the pharmaceutical industry and documents cases of fraud and corruption.

Marcia Angell covered medical ethics and pharmaceutical industry practices as a former editor of The New England Journal of Medicine. Her book "The Truth About the Drug Companies" analyzes how drug pricing and marketing affect healthcare costs.

Ben Goldacre investigates scientific misconduct and pharmaceutical research practices. His books examine clinical trial data transparency and how drug companies influence medical research.